UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2213-5
Program Prior Authorization/Medical Necessity
Medications Nuedexta® (dextromethorphan/quinidine)
P&T Approval Date 7/2020, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Nuedexta, a combination product containing dextromethorphan hydrobromide and quinidine
sulfate, is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a
variety of neurologic conditions, and is characterized by involuntary, sudden, and frequent
episodes of laughing and/or crying. PBA episodes typically occur out of proportion or are
inappropriate to the underlying emotional state. PBA is a specific condition, distinct from other
types of emotional lability that may occur in patients with neurological disease or injury.
2. Coverage Criteriaa:
A. Initial Authorization
1. Nuedexta will be approved based on all of the following criteria:
a. Diagnosis of pseudobulbar affect
-AND-
b. One of the following
1) Amyotrophic lateral sclerosis (ALS)
2) Alzheimer's disease
3) Multiple sclerosis (MS)
4) Parkinson's disease
5) Stroke
6) Traumatic brain injury
-AND-
c. Documented absence of cardiac rhythm disorders
-AND-
d. Prescribed by or in consultation with a neurologist
Authorization will be issued for 12 months.
B. Reauthorization
1. Nuedexta will be approved based on the following criterion:
© 2024 UnitedHealthcare Services, Inc.
1
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Nuedexta [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.
2. Ahmed, A, Simmons, Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk
Manag. 2013: 9; 483-89.
Program Prior Authorization/Medical Necessity – Nuedexta
Change Control
7/2020 New program.
7/2021 Annual review. Updated references.
7/2022 Annual review. Updated authorization to 6 months. Updated references.
7/2023 Annual review. No changes.
7/2024 Annual review. Updated initial authorization to 12 months.
© 2024 UnitedHealthcare Services, Inc.
2